Cancer cell · 2024
A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial.
СтатьяКлиническое исследование II фазыНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shang Xiaobin, Xie Yongjie, Yu Jinpu, Zhang Chen, Zhao Gang, Liang Fei, Liu Liang, Zhang Weihong, Li Runmei, Yu Wenwen, Yue Jie, Chen Chuangui, Duan Xiaofeng, Ma Zhao, Chen Zuoyu, Xiong Yanjuan, Yang Fan, Xiao Jianyu, Zhang Rui, Liu Pengpeng, Cheng Yanan, Cao Fuliang, Guo Feng, Liu Guoyan, Meng Bin, Zhou Dejun, Sun Yan, Ren Xiubao, Yu Jun, Hao Jihui, Jiang Hongjing
Аннотация
In this phase II study, 47 patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) received three cycles of pembrolizumab plus chemotherapy, followed by Da Vinci robot-assisted surgery. The primary endpoints were safety and major pathological response (MPR). Key secondary endpoints included complete pathological response (pCR) and survival. No grade ≥3 adverse events or surgical delays occurred during neoadjuvant therapy. Among 46 patients studied for efficacy, the MPR and pCR rates were 72% and 41%, respectively. After a median follow-up of 27.2 months, the 2-year overall survival (OS) and disease-free survival (DFS) rates were 91% and 89%, respectively. Expansion of TRGC2+ NKT cells in peripheral blood correlated with neoadjuvant treatment effectiveness, which was validated by in vitro organoid experiments and external cancer datasets, and its functional classification and mechanism of action were further explored. These findings show preoperative pembrolizumab plus chemotherapy is a promising therapeutic strategy for resectable ESCC.